<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Csl Ltd — News on 6ix</title>
    <link>https://6ix.com/company/csl-ltd</link>
    <description>Latest news and press releases for Csl Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 09 Mar 2026 15:01:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/csl-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6836636e78dffbe2df15cc32.webp</url>
      <title>Csl Ltd</title>
      <link>https://6ix.com/company/csl-ltd</link>
    </image>
    <item>
      <title>CSL announces expansion of Illinois plasma therapy manufacturing facility</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-announces-expansion-of-illinois-plasma-therapy-manufacturing-facility</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-announces-expansion-of-illinois-plasma-therapy-manufacturing-facility</guid>
      <pubDate>Mon, 09 Mar 2026 15:01:00 GMT</pubDate>
      <description>CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in Kankakee, Illinois. The expansion, a cornerstone of the company&apos;s global manufacturing growth strategy and effort to expand its U.S. production presence, was officially announced with state and local officials, including Illinois Governor JB Pritzker, Illinois State Senator Patrick Joyce, and other key dignitaries. The newly expanded facility will substant</description>
    </item>
    <item>
      <title>Canada and CSL Seqirus, a Global Leader in Influenza Vaccines, agree on new Pandemic Preparedness Contract</title>
      <link>https://6ix.com/company/csl-ltd/news/canada-and-csl-seqirus-a-global-leader-in-influenza-vaccines-agree-on-new-pandemic-preparedness-contract</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/canada-and-csl-seqirus-a-global-leader-in-influenza-vaccines-agree-on-new-pandemic-preparedness-contract</guid>
      <pubDate>Fri, 06 Mar 2026 14:00:00 GMT</pubDate>
      <description>CSL Seqirus has been awarded a new contract agreement to support the influenza pandemic preparedness plans of the Canadian government&apos;s Public Health Agency of Canada (PHAC).</description>
    </item>
    <item>
      <title>CSL Half Year Results Investor Presentation</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-half-year-results-investor-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-half-year-results-investor-presentation</guid>
      <pubDate>Wed, 11 Feb 2026 02:07:03 GMT</pubDate>
      <description>CSL Half Year Results Investor Presentation</description>
    </item>
    <item>
      <title>CSL Statutory Accounts for the Half Year Ended 31 December</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-statutory-accounts-for-the-half-year-ended-31-december</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-statutory-accounts-for-the-half-year-ended-31-december</guid>
      <pubDate>Wed, 11 Feb 2026 02:02:03 GMT</pubDate>
      <description>CSL Statutory Accounts for the Half Year Ended 31 December</description>
    </item>
    <item>
      <title>CSL Half Year Results Announcement</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-half-year-results-announcement</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-half-year-results-announcement</guid>
      <pubDate>Wed, 11 Feb 2026 02:02:02 GMT</pubDate>
      <description>CSL Half Year Results Announcement</description>
    </item>
    <item>
      <title>Paul McKenzie retires, Gordon Naylor appointed interim CEO</title>
      <link>https://6ix.com/company/csl-ltd/news/paul-mckenzie-retires-gordon-naylor-appointed-interim-ceo</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/paul-mckenzie-retires-gordon-naylor-appointed-interim-ceo</guid>
      <pubDate>Tue, 10 Feb 2026 10:26:03 GMT</pubDate>
      <description>Paul McKenzie retires, Gordon Naylor appointed interim CEO</description>
    </item>
    <item>
      <title>Deutsche Bank Appointed as Successor Depositary Bank for the American Depositary Receipt Program of CSL Limited</title>
      <link>https://6ix.com/company/csl-ltd/news/deutsche-bank-appointed-as-successor-depositary-bank-for-the-american-depositary-receipt-program-of-csl-limited</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/deutsche-bank-appointed-as-successor-depositary-bank-for-the-american-depositary-receipt-program-of-csl-limited</guid>
      <pubDate>Tue, 27 Jan 2026 19:06:00 GMT</pubDate>
      <description>NEW YORK, January 27, 2026--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited.</description>
    </item>
    <item>
      <title>Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years</title>
      <link>https://6ix.com/company/csl-ltd/news/data-published-england-journal-medicine-170100514</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/data-published-england-journal-medicine-170100514</guid>
      <pubDate>Sun, 07 Dec 2025 17:01:00 GMT</pubDate>
      <description>Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec-drlb) in adults living with hemophilia B. Published in the New England Journal of Medicine (NEJM) and presented simultaneously at the American Society of Hematology (ASH) Annual Meeting, the data reaffirm HEMGENIX&apos;s consistent performance over time to del</description>
    </item>
    <item>
      <title>CSL Capital Markets Day</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-capital-markets-day</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-capital-markets-day</guid>
      <pubDate>Wed, 05 Nov 2025 03:30:12 GMT</pubDate>
      <description>CSL Capital Markets Day</description>
    </item>
    <item>
      <title>CSL 2025 AGM Chair and CEO Speech and Presentation</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-2025-agm-chair-and-ceo-speech-and-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-2025-agm-chair-and-ceo-speech-and-presentation</guid>
      <pubDate>Tue, 28 Oct 2025 02:27:24 GMT</pubDate>
      <description>CSL 2025 AGM Chair and CEO Speech and Presentation</description>
    </item>
    <item>
      <title>CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-honoured-overall-winner-2025-023000729</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-honoured-overall-winner-2025-023000729</guid>
      <pubDate>Mon, 27 Oct 2025 02:30:00 GMT</pubDate>
      <description>CSL&apos;s base fractionation facility in Broadmeadows, Australia has been recognised as the Overall Winner of the 2025 Facility of the Year Award (FOYA) by the International Society for Pharmaceutical Engineering (ISPE).</description>
    </item>
    <item>
      <title>Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines</title>
      <link>https://6ix.com/company/csl-ltd/news/recent-rwe-data-show-cell-123000008</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/recent-rwe-data-show-cell-123000008</guid>
      <pubDate>Tue, 21 Oct 2025 12:30:00 GMT</pubDate>
      <description>CSL Seqirus, a business of CSL (ASX: CSL), announced recent data showing that cell-based influenza vaccines offer greater protection in preventing test-confirmed influenza compared to standard egg-based vaccines in a study among individuals six months to 64 years of age.1</description>
    </item>
    <item>
      <title>CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-behring-signs-letter-intent-120000800</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-behring-signs-letter-intent-120000800</guid>
      <pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
      <description>CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of HEMGENIX® (etranacogene dezaparvovec). HEMGENIX is the first one-time gene therapy authorized by Health Canada for the treatment of adults with hemophilia B who require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. The successful completion of the LOI</description>
    </item>
    <item>
      <title>CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-vifor-travere-therapeutics-recognize-063000105</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-vifor-travere-therapeutics-recognize-063000105</guid>
      <pubDate>Fri, 26 Sep 2025 06:30:00 GMT</pubDate>
      <description>CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress for people living with IgAN and the clinicians who treat</description>
    </item>
    <item>
      <title>VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment</title>
      <link>https://6ix.com/company/csl-ltd/news/varmx-partners-with-csl-in-a-strategic-collaboration-and-option-agreement-to-develop-novel-investigational-coagulation-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/varmx-partners-with-csl-in-a-strategic-collaboration-and-option-agreement-to-develop-novel-investigational-coagulation-treatment</guid>
      <pubDate>Tue, 16 Sep 2025 06:00:00 GMT</pubDate>
      <description>LEIDEN, Netherlands, September 16, 2025--VarmX partners with CSL in a strategic collaboration and option agreement to develop novel investigational blood coagulation treatment VMX-C001.</description>
    </item>
    <item>
      <title>CSL partners on new coagulation treatment</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-partners-on-new-coagulation-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-partners-on-new-coagulation-treatment</guid>
      <pubDate>Tue, 16 Sep 2025 02:22:10 GMT</pubDate>
      <description>CSL partners on new coagulation treatment</description>
    </item>
    <item>
      <title>CSL FY25 Results and Major Strategic Initiatives</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-fy25-results-and-major-strategic-initiatives</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-fy25-results-and-major-strategic-initiatives</guid>
      <pubDate>Tue, 19 Aug 2025 02:01:23 GMT</pubDate>
      <description>CSL FY25 Results and Major Strategic Initiatives</description>
    </item>
    <item>
      <title>CSL Results Presentation</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-results-presentation</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-results-presentation</guid>
      <pubDate>Tue, 19 Aug 2025 02:01:16 GMT</pubDate>
      <description>CSL Results Presentation</description>
    </item>
    <item>
      <title>CSL Statutory Accounts for FY2025</title>
      <link>https://6ix.com/company/csl-ltd/news/csl-statutory-accounts-for-fy2025</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/csl-statutory-accounts-for-fy2025</guid>
      <pubDate>Tue, 19 Aug 2025 02:00:12 GMT</pubDate>
      <description>CSL Statutory Accounts for FY2025</description>
    </item>
    <item>
      <title>Health Canada Has Authorized CSL&apos;s ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)</title>
      <link>https://6ix.com/company/csl-ltd/news/health-canada-authorized-csls-andembry-120000111</link>
      <guid isPermaLink="true">https://6ix.com/company/csl-ltd/news/health-canada-authorized-csls-andembry-120000111</guid>
      <pubDate>Fri, 08 Aug 2025 12:00:00 GMT</pubDate>
      <description>Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that Health Canada has granted a marketing authorization for ANDEMBRY® (garadacimab) for routine prevention of attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. ANDEMBRY is a monoclonal antibody designed to target activated FXII (FXIIa), a plasma protein at the top of the HAE cascade that plays a key role in attacks of swelling in people with HAE. ANDEMBRY reinforces CSL&apos;s decades</description>
    </item>
  </channel>
</rss>